KLK3 and neoplasm: A phase 2 study is planned combining maintenance pembrolizumab with repeated doses of 177Lu-PSMA-617 delivered at variable intervals dependent on PSA and PSMA PET-defined progression to prime and re-prime the anti-tumour response (NCT05766371).